Possible cooperative interactions between activation of BRAF/MEK/ERK and RASA1/R-Ras/Ral-A pathways may explain the observed decreased overall survival of melanoma patients, who have low levels of RASA1 expression and BRAF mutations (Figure 3 and Figure 8). The gene discussed is RRAS; the disease is melanoma.